Holen Sie sich die Stockscreener-App
5.01
2.91%
-0.15
Handel nachbörslich:
5.00
-0.010
-0.20%
Schlusskurs vom Vortag:
$5.16
Offen:
$5.2
24-Stunden-Volumen:
5.76M
Relative Volume:
1.26
Marktkapitalisierung:
$1.19B
Einnahmen:
$251.85M
Nettoeinkommen (Verlust:
$-72.58M
KGV:
-15.99
EPS:
-0.3134
Netto-Cashflow:
$-63.80M
1W Leistung:
-1.18%
1M Leistung:
+7.51%
6M Leistung:
-12.87%
1J Leistung:
-41.20%
1-Tages-Spanne:
$5.00
$5.29
1-Wochen-Bereich:
$4.98
$6.07
52-Wochen-Spanne:
$4.32
$10.13
Ardelyx Inc Stock (ARDX) Company Profile
Firmenname
Ardelyx Inc
Sektor
Branche
Telefon
510-745-7047
Adresse
34175 ARDENWOOD BLVD., FREMONT, CA
Vergleichen Sie ARDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.01 | 1.19B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2023-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-25 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-11-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Herabstufung | Jefferies | Buy → Hold |
| 2021-07-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-23 | Eingeleitet | Wedbush | Outperform |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Fortgesetzt | Citigroup | Buy |
| 2020-02-18 | Fortgesetzt | Jefferies | Buy |
| 2020-02-12 | Eingeleitet | Citigroup | Buy |
| 2020-02-10 | Eingeleitet | Cowen | Outperform |
| 2019-04-08 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-24 | Eingeleitet | Jefferies | Buy |
| 2018-03-19 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-29 | Bestätigt | Citigroup | Buy |
| 2017-11-22 | Bestätigt | Ladenburg Thalmann | Buy |
| 2017-10-17 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-03-31 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-09 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
Recent 15% pullback isn't enough to hurt long-term Ardelyx (NASDAQ:ARDX) shareholders, they're still up 504% over 3 years - Simply Wall St
Ardelyx (NASDAQ:ARDX) Earns Neutral Rating from HC Wainwright - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Shares Purchased by Hennion & Walsh Asset Management Inc. - MarketBeat
Ardelyx (NASDAQ:ARDX) Shares Up 8.3%Still a Buy? - MarketBeat
Ardelyx (NASDAQ:ARDX) Stock Price Down 3.7%Time to Sell? - MarketBeat
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last? - MSN
Ardelyx (NASDAQ:ARDX) Stock Price Up 8.3%What's Next? - MarketBeat
Ardelyx's Ibsrela sales beat expectations, shares surge By Investing.com - Investing.com Canada
Ardelyx reports strong 2024 sales, eyes growth in 2025 By Investing.com - Investing.com Canada
Ardelyx provides update on commercial progress; shares up 8% - MSN
Ardelyx reports strong 2024 sales, eyes growth in 2025 - Investing.com
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities - The Manila Times
Ardelyx Reports Strong 2024: IBSRELA, XPHOZAH Drive $319M Revenue as Growth Accelerates - StockTitan
Ardelyx CEO Michael Raab sells $221k in stock - Investing.com India
Ardelyx CEO Michael Raab sells $221k in stock By Investing.com - Investing.com Australia
Ardelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 41,666 Shares - MarketBeat
Ardelyx (NASDAQ:ARDX) Shares Up 5.8%Should You Buy? - MarketBeat
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Ardelyx CEO to Present at JP Morgan Healthcare Conference 2025 in San Francisco - StockTitan
Ardelyx, Inc. (NASDAQ:ARDX) Receives $10.07 Average PT from Brokerages - MarketBeat
Principal Financial Group Inc. Has $933,000 Stock Holdings in Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Ardelyx Stock - Benzinga
Jefferies Financial Group Issues Pessimistic Forecast for Ardelyx (NASDAQ:ARDX) Stock Price - MarketBeat
(ARDX) Investment Analysis - Stock Traders Daily
Ardelyx (NASDAQ:ARDX) Stock Price Down 3.8%Here's Why - MarketBeat
Why Ardelyx (ARDX) Is One of the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey
Exploring 3 High Growth Tech Stocks in the United States - Simply Wall St
Lost Money on Ardelyx, Inc.(ARDX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - The Eastern Progress Online
Ardelyx (NASDAQ:ARDX) Stock Price Up 4.6%What's Next? - MarketBeat
US Penny Stocks To Watch In December 2024 - Simply Wall St
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus.com
Ardelyx (NASDAQ:ARDX) Shares Gap Up After Insider Buying Activity - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Director David M. Mott Purchases 213,300 Shares - MarketBeat
Ardelyx director David Mott buys $996,580 in stock By Investing.com - Investing.com Nigeria
Ardelyx director David Mott buys $996,580 in stock - Investing.com
Ardelyx, Inc. (NASDAQ:ARDX) Shares Bought by Barclays PLC - MarketBeat
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - The Eastern Progress Online
Ardelyx: A Small Bet Its Latest Setback Will Be Temporary (NASDAQ:ARDX) - Seeking Alpha
Ardelyx stock hits 52-week low at $4.34 amid market challenges - Investing.com Canada
Finanzdaten der Ardelyx Inc-Aktie (ARDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):